Frontotemporal Disorders Treatment Market
Market Insights on Frontotemporal Disorders Treatment covering sales outlook, demand forecast & up-to-date key trends
Frontotemporal Disorders Treatment Market by Drug Class (Cognitive Enhancers, Antipsychotics, Antidepressants), by Treatment (Behavioral Symptoms Management, Psychological Symptoms Management) & Region for 2022-2028
Frontotemporal Disorders Treatment Market Overview
[213 Pages Report] The global Frontotemporal Disorders Treatment Market value at around US$ 343.8 Mn in 2022, registering Y-o-Y growth of 4.4%. The market is projected to increase at a CAGR of 4.6% and reach a valuation of US$ 451.4 Mn by 2028.
|
Frontotemporal Disorders Treatment Market Size (2022) |
US$ 343.8 Mn |
|
Sales Forecast (2028) |
US$ 451.4 Mn |
|
Global Market Growth Rate (2022 to 2028) |
4.6% CAGR |
|
Share of Top 5 Frontotemporal Disorders Treatment System Providers |
50% |
Currently, frontotemporal disorders treatment holds a share of 4.4% of the global neurological disorder treatment market.
Let us know your requirement to get
100% FREE customization
Frontotemporal Disorders Treatment Demand Analysis (2013-2021) Compared to Market Forecasts (2022-2028)
“Growing Prevalence of Dementia Expected to Propel Demand for Frontotemporal Disorders Treatment Drugs”
During the historical period of 2013 to 2021, the frontotemporal disorders treatment market expanded at a CAGR of 4.4%.
Frontotemporal disorders are a bunch of rare disorders that include shrinkage of a particular portion of the brain that controls personality, language, and behavior. The condition arises due to the degeneration of frontotemporal cells, which is called frontotemporal lobar degeneration (FTLD).
The typical age range for the onset of frontotemporal dementia is 40 to 60 years; however, it can start after 60 years of age, and the maximum life expectancy after diagnosis is 8–10 years.
With severe dearth of frontotemporal disorders treatment drugs for the reliable treatment of frontotemporal disorders, treatment continues to underscore the growing significance of disease management. As frontotemporal disorders treatment exclusively includes symptomatic efforts to date, the condition continues to attract research interests worldwide.
Available frontotemporal disorders treatment drugs and other means of frontotemporal disorders treatment do not stop or even decelerate frontotemporal disorders progression, which further remains a key driving force for growing demand for frontotemporal disorders treatment. Expanding incentives for orphan drug development is identified as a prominent factor pushing revenue growth of the frontotemporal disorders treatment industry.
Considering the aforementioned factors, the global frontotemporal disorders treatment market is anticipated to rise at 4.6% CAGR across the 2022 to 2028 time frame.
What are the Prominent Driving Factors for Frontotemporal Disorders Treatment?
“Increasing FTD Drug Development Grants & Funding by Non-Profit Organizations Driving Market Growth”
Non-profit organizations and disease advocacy & private organizations currently are focusing on supporting FTD drug development as the patient base of FTD is expanding. Research funding initiatives by non-profit organizations such as the Association for Frontotemporal Degeneration (AFTD), Alzheimer Discovery Foundation (ADDF), Bluefield Project Organization, Tau Consortium Organization, and CurePSP, Inc. have helped promote research initiatives in frontotemporal disorders treatment drugs.
These organizations support clinical trials as well as preclinical studies for testing new therapeutics that are interventional to slow or stop FTD and other rare neurological disease progressions.
Rising life expectancy rate is another major factor expected to boost the growth of the frontotemporal disorders treatment market due to the high prevalence of neurological disease among the older population. Population aged 65 years and above is mostly prone to neurodegenerative diseases such as frontotemporal disorder, Alzheimer’s, and dementia.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhich Factors are Restraining Demand for Frontotemporal Disorders Treatment?
“Misdiagnosis and Lack of Awareness Limiting Adoption of Neurological Conditions Treatment”
Frontotemporal disorders are often misdiagnosed as depression, Parkinson’s, Alzheimer’s, or other psychiatric conditions, thereby limiting the scope of adoption of neurological conditions treatment.
Though clinical trials have resulted in many interventions other than medication, consistently high rate of clinical trial failures is a significant factor that is influencing the growth prospects of neurological conditions treatment.
Which is the Dominant Regional Market for Frontotemporal Disorders Treatment?
“Ongoing Clinical Trials for Frontotemporal Lobar Degeneration (FTLD) to Boost Market Expansion in Western Europe”
Western Europe is expected to contribute 30.5% share in the global frontotemporal disorders treatment market in 2022.
While rapidly growing FTD prevalence and expanding ongoing clinical trials platforms are providing a collective push to the frontotemporal disorders treatment market in Western Europe, research estimates rapid emergence owing to increasing sophistication of the healthcare sector and gradually surging awareness about frontotemporal lobar degeneration (FTLD).
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Country-wise Analysis
What Potential Does the U.S. Frontotemporal Disorders Treatment Market Hold?
“Orphan Drug Development Incentives by FDA to Push the Market Forward”
Frontotemporal dementia falls under rare diseases or orphan indications. FTD affects around 30,000 to 40,000 patients in the U.S. Treatment of FTD falls under auspices of the Orphan Drug Act of 1983 as orphan drug indications are those that affect less than 200,000 people in the U.S.
Orphan drug designation to FTD allows the continuation of clinical trial and orphan drug development with commercial incentives, prioritized consultation by FDA on clinical studies, and reduction in regulatory fees.
Presence of advanced healthcare facilities, stronger purchasing power for expensive pharmaceuticals, reimbursement regulations, and an expanding patient pool is expected to fuel market growth in the U.S.
How is the Market for Frontotemporal Disorders Treatment Faring in China?
“Higher Prevalence of Frontotemporal Disorders in Older Age Group to Fuel Market Expansion”
China, with an attractive revenue contribution at present, is projected to remain a highly lucrative regional market for potential investors in the frontotemporal disorders treatment systems market.
The market in China is predicted to develop at the quickest rate due to increased disposable income. Moreover, the market growth is related to increasing prevalence of frontotemporal disorders due to the growing elderly population base, as well as the poor immune system.
Category-wise Insights
Which Disease Indication Will Hold Maximum Sway?
“Initiatives by Mental Treatment Centers for Frontotemporal Dementia Patients to Boost Market Growth”
Based on disease indication, frontotemporal dementia (FTD), holding a massive market value share, remains the most common indication among all that continues to capture clinical research interests.
Rapid development of new frontotemporal dementia therapies will push collaborative activities among clinical research entities, educational institutions, academic laboratories, pharma and biotech centers, and the FDA.
Furthermore, frontotemporal dementia therapeutics are anticipated to witness major contributions from pharmaceutical companies – eventually boosting the funding and clinical trial scenario.
Which Distribution Channel is Driving Demand for Frontotemporal Disorders Treatment Products?
“Hospital Pharmacies Most Preferred Due to Easy Availability of Frontotemporal Disorders Treatment Drugs”
Hospital pharmacies are expected to hold the highest market share over the forecast period. Majority of frontotemporal problems are treated in hospitals, and with the availability of trained medical personnel, it is simpler to control an individual's health more correctly.
However, there are no specific treatments available to entirely stop the course of frontotemporal disorders. As a result, doctors may prescribe antidepressant medicines to help with anxiety and other symptoms.
Impact of COVID-19 on Market
The frontotemporal disorders treatment market, like many others, was heavily damaged by the COVID-19 pandemic. An increase in infection fear among persons of all ages has resulted from an increasing number of COVID-positive cases that have resulted in mortality and morbidity all across the world.
In addition, limits on travel and movement, social distance conventions, and hospital beds reserved for COVID patients reduced clinical and hospital visits.
However, the emergence of virtual healthcare consultations and remote patient monitoring, as well as an increase in COVID-19 vaccines and lifting of lockdown limitations, will enable the market for frontotemporal disorders treatment devices to quickly recover and grow significantly over the coming years.
Competitive Landscape
In a highly fragmented landscape of the global frontotemporal disorders treatment market, almost 70% of companies offer generics as their key drug offerings. Operated by a large number of prominent international, multinational, and regional players, the market for frontotemporal disorders treatment is recently witnessing a heap of strategic deals, including acquisitions, collaborations, and alliances.
For instance,
- AstraZeneca Plc recently inked an agreement with Luye Pharma Group, Ltd. over the licensing and sales of Seroquel and Seroquel XR across China and the U.K, in addition to a few other international markets. The drug is occasionally used to address a set of behavioral problems associated with FTD.
Frontotemporal Disorders Treatment Industry Report Scope
|
Attribute |
Details |
|
Forecast Period |
2022-2028 |
|
Historical Data Available for |
2013-2021 |
|
Market Analysis |
Value in US$ Mn |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Pricing |
Available upon Request |
Key Segments of Frontotemporal Disorders Treatment Industry Research
By Drug Class:
- Cognitive Enhancers
- Antipsychotics
- Antidepressants
- CNS Stimulants
- Others
By Treatment:
- Behavioral Symptoms Management
- Psychological Symptoms Management
By Disease Indication:
- Frontotemporal Dementia
- Primary Progressive Aphasia
- Movement Disorders
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
By Region:
- North America Frontotemporal Disorders Treatment Market
- Latin America Frontotemporal Disorders Treatment Market
- Europe Frontotemporal Disorders Treatment Market
- East Asia Frontotemporal Disorders Treatment Market
- South Asia & Pacific Frontotemporal Disorders Treatment Market
- Middle East & Africa (MEA) Frontotemporal Disorders Treatment Market
Frequently Asked Questions
As of 2022, the global frontotemporal disorders treatment market is expected to reach US$ 343.8 Mn.
France, China, Germany, India, and the U.S. are the top 5 countries driving most demand for frontotemporal disorders treatment.
Pfizer Inc., Johnson & Johnson, Sanofi S.A., Eli Lilly and Company, and GlaxoSmithKline Plc. are leading companies in this market.
The frontotemporal disorders treatment market is expected to rise at a CAGR of around 4.6% during the period of 2022-2028.
Western Europe accounts for 30.5% share of the global frontotemporal disorders treatment market.
1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3. Frontotemporal Disorders Treatment Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis & Pipeline Assessment
4. Market Background
4.1. Market Dynamics
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Trends
5. Key Inclusions
5.1. Disease Epidemiology
6. North America Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028
6.1. Introduction
6.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021
6.2.1. U.S.
6.2.2. Canada
6.3. Market Value (US$ Mn) Forecast By Country, 2022–2028
6.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021
6.4.1. Cognitive Enhancers
6.4.2. Antipsychotics
6.4.3. Antidepressants
6.4.4. CNS Stimulants
6.4.5. Others
6.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028
6.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021
6.6.1. Behavioral Symptom Management
6.6.2. Psychological Symptoms Management
6.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028
6.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021
6.8.1. Frontotemporal Dementia
6.8.2. Primary Progressive Aphasia
6.8.3. Movement Disorders
6.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028
6.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
6.10.1. Hospital Pharmacies
6.10.2. Retail Pharmacy
6.10.3. Drug Stores
6.10.4. Online Pharmacy
6.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028
6.12. Market Attractiveness Analysis
6.12.1. By Country
6.12.2. By Drug Class
6.12.3. By Treatment Type
6.12.4. By Disease Indication
6.12.5. By Distribution Channel
7. Latin America Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028
7.1. Introduction
7.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Market Value (US$ Mn) Forecast By Country, 2022–2028
7.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021
7.4.1. Cognitive Enhancers
7.4.2. Antipsychotics
7.4.3. Antidepressants
7.4.4. CNS Stimulants
7.4.5. Others
7.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028
7.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021
7.6.1. Behavioral Symptom Management
7.6.2. Psychological Symptoms Management
7.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028
7.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021
7.8.1. Frontotemporal Dementia
7.8.2. Primary Progressive Aphasia
7.8.3. Movement Disorders
7.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028
7.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
7.10.1. Hospital Pharmacies
7.10.2. Retail Pharmacy
7.10.3. Drug Stores
7.10.4. Online Pharmacy
7.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028
7.12. Market Attractiveness Analysis
7.12.1. By Country
7.12.2. By Drug Class
7.12.3. By Treatment Type
7.12.4. By Disease Indication
7.12.5. By Distribution Channel
8. Western Europe Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028
8.1. Introduction
8.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021
8.2.1. Germany
8.2.2. U.K
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Western Europe
8.3. Market Value (US$ Mn) Forecast By Country, 2022–2028
8.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021
8.4.1. Cognitive Enhancers
8.4.2. Antipsychotics
8.4.3. Antidepressants
8.4.4. CNS Stimulants
8.4.5. Others
8.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028
8.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021
8.6.1. Behavioral Symptom Management
8.6.2. Psychological Symptoms Management
8.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028
8.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021
8.8.1. Frontotemporal Dementia
8.8.2. Primary Progressive Aphasia
8.8.3. Movement Disorders
8.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028
8.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
8.10.1. Hospital Pharmacies
8.10.2. Retail Pharmacy
8.10.3. Drug Stores
8.10.4. Online Pharmacy
8.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028
8.12. Market Attractiveness Analysis
8.12.1. By Country
8.12.2. By Drug Class
8.12.3. By Treatment Type
8.12.4. By Disease Indication
8.12.5. By Distribution Channel
9. Eastern Europe Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028
9.1. Introduction
9.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021
9.2.1. Russia
9.2.2. Poland
9.2.3. Rest of Eastern Europe
9.3. Market Value (US$ Mn) Forecast By Country, 2022–2028
9.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021
9.4.1. Cognitive Enhancers
9.4.2. Antipsychotics
9.4.3. Antidepressants
9.4.4. CNS Stimulants
9.4.5. Others
9.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028
9.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021
9.6.1. Behavioral Symptom Management
9.6.2. Psychological Symptoms Management
9.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028
9.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021
9.8.1. Frontotemporal Dementia
9.8.2. Primary Progressive Aphasia
9.8.3. Movement Disorders
9.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028
9.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
9.10.1. Hospital Pharmacies
9.10.2. Retail Pharmacy
9.10.3. Drug Stores
9.10.4. Online Pharmacy
9.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028
9.12. Market Attractiveness Analysis
9.12.1. By Country
9.12.2. By Drug Class
9.12.3. By Treatment Type
9.12.4. By Disease Indication
9.12.5. By Distribution Channel
10. Asia Pacific Excluding Japan (APEJ) Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028
10.1. Introduction
10.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021
10.2.1. India
10.2.2. China
10.2.3. Australia
10.2.4. ASEAN
10.2.5. Rest of APEJ
10.3. Market Value (US$ Mn) Forecast By Country, 2022–2028
10.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021
10.4.1. Cognitive Enhancers
10.4.2. Antipsychotics
10.4.3. Antidepressants
10.4.4. CNS Stimulants
10.4.5. Others
10.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028
10.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021
10.6.1. Behavioral Symptom Management
10.6.2. Psychological Symptoms Management
10.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028
10.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021
10.8.1. Frontotemporal Dementia
10.8.2. Primary Progressive Aphasia
10.8.3. Movement Disorders
10.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028
10.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
10.10.1. Hospital Pharmacies
10.10.2. Retail Pharmacy
10.10.3. Drug Stores
10.10.4. Online Pharmacy
10.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028
10.12. Market Attractiveness Analysis
10.12.1. By Country
10.12.2. By Drug Class
10.12.3. By Treatment Type
10.12.4. By Disease Indication
10.12.5. By Distribution Channel
11. Japan Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028
11.1. Introduction
11.2. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021
11.2.1. Cognitive Enhancers
11.2.2. Antipsychotics
11.2.3. Antidepressants
11.2.4. CNS Stimulants
11.2.5. Others
11.3. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028
11.4. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021
11.4.1. Behavioral Symptom Management
11.4.2. Psychological Symptoms Management
11.5. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028
11.6. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021
11.6.1. Frontotemporal Dementia
11.6.2. Primary Progressive Aphasia
11.6.3. Movement Disorders
11.7. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028
11.8. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacy
11.8.3. Drug Stores
11.8.4. Online Pharmacy
11.9. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028
11.10. Market Attractiveness Analysis
11.10.1. By Country
11.10.2. By Drug Class
11.10.3. By Treatment Type
11.10.4. By Disease Indication
11.10.5. By Distribution Channel
12. Middle East and Africa Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028
12.1. Introduction
12.2. Historical Market Value (US$ Mn) Analysis By Country, 2013-2021
12.2.1. GCC Countries
12.2.2. South Africa
12.2.3. Rest of MEA
12.3. Market Value (US$ Mn) Forecast By Country, 2022–2028
12.4. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021
12.4.1. Cognitive Enhancers
12.4.2. Antipsychotics
12.4.3. Antidepressants
12.4.4. CNS Stimulants
12.4.5. Others
12.5. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028
12.6. Historical Market Value (US$ Mn) Trend Analysis By Treatment Type, 2013-2021
12.6.1. Behavioral Symptom Management
12.6.2. Psychological Symptoms Management
12.7. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028
12.8. Historical Market Value (US$ Mn) Trend Analysis By Disease Indication, 2013-2021
12.8.1. Frontotemporal Dementia
12.8.2. Primary Progressive Aphasia
12.8.3. Movement Disorders
12.9. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028
12.10. Historical Market Value (US$ Mn) Trend Analysis By Distribution Channel, 2013-2021
12.10.1. Hospital Pharmacies
12.10.2. Retail Pharmacy
12.10.3. Drug Stores
12.10.4. Online Pharmacy
12.11. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028
12.12. Market Attractiveness Analysis
12.12.1. By Country
12.12.2. By Drug Class
12.12.3. By Treatment Type
12.12.4. By Disease Indication
12.12.5. By Distribution Channel
13. Forecast Factors: Relevance and Impact
14. Driver Restraint Impact Analysis
15. Market Structure Analysis
16. Competition Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Profitability and Gross Margin Analysis By Competition
16.4. Competitors Deep Dive (Company Overview, Footprint, Strategies, Financials, Key Development)
16.4.1. Pfizer Inc.
16.4.2. Johnson & Johnson
16.4.3. Sanofi S.A.
16.4.4. Eli Lilly and Company
16.4.5. GlaxoSmithKline Plc.
16.4.6. GlaxoSmithKline Plc.
16.4.7. Mylan N.V.
16.4.8. Merck & Company, Inc.
16.4.9. AstraZeneca plc.
16.4.10. Allergan Plc.
17. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028 By Region
17.1. Introduction / Key Findings
17.2. Historical Market Value (US$ Mn) Analysis By Region
17.2.1. North America
17.2.2. Western Europe
17.2.3. Eastern Europe
17.2.4. Latin America
17.2.5. Asia Pacific Excluding Japan
17.2.6. Japan
17.2.7. Middle East and Africa
17.3. Market Value (US$ Mn) Forecast By Region
17.4. Market Attractiveness Analysis By Region
18. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028, By Drug Class
18.1. Introduction/Key Finding
18.2. Historical Market Value (US$ Mn) Analysis By Drug Class, 2013-2021
18.2.1. Cognitive Enhancers
18.2.2. Antipsychotics
18.2.3. Antidepressants
18.2.4. CNS Stimulants
18.2.5. Others
18.3. Market Value (US$ Mn) Forecast By Drug Class, 2022–2028
18.4. Market Attractiveness Analysis By Drug Class
19. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028, By Treatment Type
19.1. Introduction/Key Finding
19.2. Historical Market Value (US$ Mn) Analysis By Treatment Type, 2013-2021
19.2.1. Frontotemporal Dementia
19.2.2. Primary Progressive Aphasia
19.2.3. Movement Disorders
19.3. Market Value (US$ Mn) Forecast By Treatment Type, 2022–2028
19.4. Market Attractiveness Analysis By Treatment Type
20. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028, By Disease Indication
20.1. Introduction/Key Finding
20.2. Historical Market Value (US$ Mn) Analysis By Disease Indication, 2013-2021
20.2.1. Frontotemporal Dementia
20.2.2. Primary Progressive Aphasia
20.2.3. Movement Disorders
20.3. Market Value (US$ Mn) Forecast By Disease Indication, 2022–2028
20.4. Market Attractiveness Analysis By Disease Indication
21. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028, By Distribution Channel
21.1. Introduction/Key Finding
21.2. Historical Market Value (US$ Mn) Analysis By Distribution Channel, 2013-2021
21.2.1. Hospital Pharmacies
21.2.2. Retail Pharmacy
21.2.3. Drug Stores
21.2.4. Online Pharmacy
21.3. Market Value (US$ Mn) Forecast By Distribution Channel, 2022–2028
21.4. Market Attractiveness Analysis By Distribution Channel
22. Global Frontotemporal Disorders Treatment Market Analysis 2013-2021 and Forecast 2022–2028
22.1. Market Value Share Analysis By All Segment
22.2. Y-o-Y Growth Analysis By All Segment
22.3. Absolute $ Opportunity
23. Assumptions and Acronyms Used
24. Research Methodology
Let us know your requirement to get
100% FREE customization
Table 01: NIH Estimated Funding for Frontotemporal Dementia
Table 02: Frontotemporal Disorders Treatment Market Opportunity Pipeline Analysis (2021)
Table 03: Frontotemporal Disorders Treatment Market Opportunity Pipeline Analysis (2021)
Table 04: Non-Profit Organizations Driving FTD Therapeutics Development
Table 05: Non-Profit Organizations Driving FTD Therapeutics Development
Table 06: World Population Aged 65 and Over by Sex: 2015, 2030, and 2050 (Numbers in millions)
Table 07: Prevalence of Frontotemporal Dementia, By Region
Table 08: Prevalence of Frontotemporal Dementia, By Region
Table 09: Prevalence of Primary Progressive Aphasia , By Region
Table 10: Prevalence of Primary Progressive Aphasia , By Region
Table 11: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country
Table 12: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
Table 13: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type
Table 14: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication
Table 15: North America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 16: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country
Table 17: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
Table 18: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type
Table 19: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication
Table 20: Latin America Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 21: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country
Table 22: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
Table 23: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type
Table 24: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication
Table 25: Western Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 26: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country
Table 27: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
Table 28: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type
Table 29: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication
Table 30: Eastern Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 31: APEJ Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country
Table 32: APEJ Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
Table 33: APEJ Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type
Table 34: APEJ Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication
Table 35: APEJ Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 36: Japan Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
Table 37: Japan Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type
Table 38: Japan Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication
Table 39: Japan Europe Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 40: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Country
Table 41: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
Table 42: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028 , By Treatment Type
Table 43: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication
Table 44: MEA Frontotemporal Disorders Treatment Market Value (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
Table 45: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Region
Table 46: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Drug Class
Table 47: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Treatment Type
Table 48: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Disease Indication
Table 49: Global Frontotemporal Disorders Treatment Market Valve (US$ Mn) Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystFigure 1: Global Frontotemporal Disorders Treatment Market Split By Drug Class (2022)
Figure 2: Global Frontotemporal Disorders Treatment Market Split Treatment Type (2022)
Figure 3: Global Frontotemporal Disorders Treatment Market Split By Distribution Channel (2022)
Figure 4: Global Frontotemporal Disorders Treatment Market Split By Disease Indication (2022)
Figure 5: Global Frontotemporal Disorders Treatment Market Split By Region (2022)
Figure 6: Economic Burden of Major Neurological Disease in United States % (2014)
Figure 7: Distribution of Industry Sponsored Clinical Programs for Frontotemporal Disorders Drugs, by Phase
Figure 8: Global Impact of Dementia
Figure 9: Incidence of FTD By Age
Figure 10: Prevalence of Frontotemporal Dementia Across the Globe
Figure 11: Prevalence of Primary Progressive Aphasia (PPA) Across the Globe
Figure 12: North America Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 13: North America Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 14: U.S. Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 15: U.S. Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 16: Canada Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 17: Canada Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 18: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country
Figure 19: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class
Figure 20: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type
Figure 21: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication
Figure 22: North America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 23: Latin America Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 24: Latin America Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 25: Brazil Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 26: Brazil Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 27: Mexico Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 28: Mexico Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 29: Rest of Latin America Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 30: Rest of Latin America Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 31: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country
Figure 32: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class
Figure 33: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type
Figure 34: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication
Figure 35: Latin America Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 36: Western Europe Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 37: Western Europe Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 38: Germany Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 39: Germany Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 40: Italy Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 41: Italy Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 42: France Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 43: France Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 44: U.K. Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 45: U.K. Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 46: Spain Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 47: Spain Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 48: Rest of Western Europe Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 49: Rest of Western Europe Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 50: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country
Figure 51: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class
Figure 52: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type
Figure 53: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication
Figure 54: Western Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 55: Eastern Europe Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 56: Eastern Europe Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 57: Russia Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 58: Russia Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 59: Poland Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 60: Poland Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 61: Rest of Eastern Europe Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 62: Rest of Eastern Europe Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 63: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country
Figure 64: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class
Figure 65: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type
Figure 66: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication
Figure 67: Eastern Europe Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 68: APEJ Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 69: APEJ Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 70: China Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 71: China Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 72: India Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 73: India Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 74: Australia Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 75: Australia Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 76: ASEAN Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 77: ASEAN Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 78: Rest of APEJ Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 79: Rest of APEJ Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 80: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country
Figure 81: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class
Figure 82: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type
Figure 83: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication
Figure 84: APEJ Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 85: Japan Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 86: Japan Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 87: Japan Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication
Figure 88: Japan Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type
Figure 89: Japan Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class
Figure 90: Japan Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 91: MEA Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 92: MEA Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 93: GCC Countries Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 94: GCC Countries Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 95: South Africa Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 96: South Afric Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 97: Rest of MEA Frontotemporal Disorders Treatment Market Value Analysis, 2013–2021
Figure 98: Rest of MEA Frontotemporal Disorders Treatment Market Forecast & Y-o-Y growth, 2022–2028
Figure 99: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Country
Figure 100: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class
Figure 101: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type
Figure 102: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication
Figure 103: MEA Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 104: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Region
Figure 105: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Drug Class
Figure 106: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Treatment Type
Figure 107: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Disease Indication
Figure 108: Global Frontotemporal Disorders Treatment Market Attractiveness Analysis, By Distribution Channel
Figure 109: Global Frontotemporal Disorders Treatment Market Historical Market Value and Y-o-Y, 2013-2022
Figure 110: Global Frontotemporal Disorders Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2028
Figure 111: Global Frontotemporal Disorders Treatment Market Absolute $ Opportunity, 2013–2028
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
